AO 120 (Rev. 08/10)

TO:

Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK

	,			
In Complia filed in the U.S. D		15 U.S.C. § 1116 you are hereby advised the Nevada	at a court action has been on the following	
☐ Trademarks or		ction involves 35 U.S.C. § 292.):	on the following	
		U.S. DISTRICT COURT		
DOCKET NO. 2:16-cv-2562	DATE FILED 11/4/2016		vada	
PLAINTIFF		DEFENDANT Dr. Reddy's Laboratories	Inc	
Amarin Pharma, Inc. Amarin Pharmaceuticals Ireland Limited		Dr. Reddy's Laboratories	Dr. Reddy's Laboratories, Inc. Dr. Reddy's Laboratories, Ltd.	
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATE	NT OR TRADEMARK	
1	See Attached Complaint			
2				
3				
4				
5				
3				
	In the above—entitled case, t	he following patent(s)/ trademark(s) have been	en included:	
DATE INCLUDED	INCLUDED BY			
	☐ Amendment ☐ Answer ☐ Cross Bill ☐ Other Pleading			
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATE	NT OR TRADEMARK	
1				
2				
3				
4				
5				
In the al	ove—entitled case, the following	g decision has been rendered or judgement is	ssued:	
DECISION/JUDGEMENT				
CLERK	I (F	SY) DEPUTY CLERK	DATE	
	1,-	,		

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

1

Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (collectively, "Defendants" or "DRL") allege as follows:

Nature of the Action 14 parteurs

This is a civil action for patent infringement arising under the patent laws of the 1. United States, 35 U.S.C. § 100 et seq., and in particular under 35 U.S.C. § 271(a-c, e) for infringement of U.S. Patent No. 8,293,728 ("the '728 Patent"), U.S. Patent No. 8,318,715 ("the '715 Patent'), U.S. Patent No. 8,357,677 ("the '677 Patent"), U.S. Patent No. 8,367,652 ("the '652 Patent'"), U.S. Patent No. 8,377,920 ("the '920 Patent"), U.S. Patent No. 8,399,446 ("the '446 Patent''), U.S. Patent No. 8,415,335 ("the '335 Patent"), U.S. Patent No. 8,426,399 ("the '399 Patent"), U.S. Patent No. 8,431,560 ("the '560 Patent"), U.S. Patent No. 8,440,650 ("the '650 Patent'), U.S. Patent No. 8,518,929 ("the '929 Patent"), U.S. Patent No. 8,524,698 ("the '698 Patent"), U.S. Patent No. 8,546,372 ("the '372 Patent"), and U.S. Patent No. 8,617,594 ("the '594 Patent"). This action relates to an Abbreviated New Drug Application ("ANDA") No. 209499 filed by or for the benefit of Defendants with the United States Food and Drug Administration ("FDA") for approval to market generic versions of Plaintiffs' VASCEPA® pharmaceutical products that are sold in the United States, including within this judicial district. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a).

The Parties

- 2. Plaintiff Amarin Pharma, Inc. is a company organized and existing under the laws of Delaware with its principal place of business at 1430 Route 206, Bedminster, NJ 07921.
- Plaintiff Amarin Pharmaceuticals Ireland Limited is a company incorporated under the laws of Ireland with registered offices at 88 Harcourt Street, Dublin 2, Dublin, Ireland.
- 4. Upon information and belief, Defendant Dr. Reddy's Laboratories, Inc. is a company organized and existing under the laws of New Jersey with its principal place of business at 107 College Road East, Princeton, New Jersey 08540.
 - 5. Upon information and belief, Defendant Dr. Reddy's Laboratories, Ltd. is a

25

26

27